

## Preferred Drug List Announcement

MO HealthNet Division (MHD) is continuing the state-specific Preferred Drug List (PDL) evaluation process. Drug/Drug classes for review for the upcoming quarter are identified at each of the quarterly meetings of the Drug Prior Authorization Committee and also posted on the Division's web page at <http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf> shortly following each meeting.

MO HealthNet Division's clinical team will conduct the clinical reviews of the drug products under evaluation each quarter. For preferred status consideration for your product, a more detailed review request should be presented to MHD.

- All clinical information for consideration should be forwarded to Karen Powell at [karen.powell@gainwelltechnologies.com](mailto:karen.powell@gainwelltechnologies.com). These submissions should generally follow the AMCP guideline format.
- Financial evaluations for these therapeutic class reviews are conducted by Gainwell Technologies, LLC. Companies wishing to discuss opportunities for supplemental rebates and/or the policy surrounding the PDL process should contact Sandy Kapur, PharmD at [sandy.kapur@gainwelltechnologies.com](mailto:sandy.kapur@gainwelltechnologies.com).
- If a public presentation is desired, please contact Carmen Burton at [Carmen.M.Burton@dss.mo.gov](mailto:Carmen.M.Burton@dss.mo.gov) or call (573) 751-6961.

The Drug PA Committee will convene at 10:00 a.m. on Thursday, December 15, 2022.

Preferred Drug List (PDL) Therapeutic Class Name	
<ul style="list-style-type: none"> <li>• Agents for Alzheimers</li> <li>• Agents for Hereditary Angioedema</li> <li>• Agents for Hypoglycemia</li> <li>• Agents for Opioid Induced Constipation</li> <li>• Analgesics, Fibromyalgia Agents</li> <li>• Analgesics, Neuropathic Pain Agents</li> <li>• Analgesics, NSAIDS</li> <li>• Analgesics, Opiate and Select Alcohol Dependence Agents</li> <li>• Analgesics, Opiate Emergency Reversal Agents</li> <li>• Analgesics, Opioids -Long-Acting Narcotics</li> <li>• Analgesics, Tramadol like agents</li> <li>• Antiandrogenic Agents</li> <li>• Anticonvulsants: Agents for Dravet's Syndrome</li> <li>• Antiemetics, 5-HT3 and NK1 Injectable Agents</li> <li>• Antiemetics, 5-HT3, NK1 &amp; Other Select Non-Injectable Agents</li> <li>• Antiemetics, THC Derivative Agents</li> <li>• Anti-Migraine, Alternative Oral Agents</li> </ul>	<ul style="list-style-type: none"> <li>• Anti-Migraine: Calcitonin gene-related peptides (CGRPs)</li> <li>• Anti-Migraine: Serotonin (5-HT1) Receptor Agonists</li> <li>• Antiparkinsonism Agents: Non-ergot dopamine agonists</li> <li>• Antiparkinson's Agents: MAOI-B Agents</li> <li>• Antipsychotics, Atypical Oral and Transdermal</li> <li>• Antipsychotics, Depot Formulations</li> <li>• Antivirals, Antiretroviral Therapy (ART)</li> <li>• IBS Agents, Anti-diarrheal</li> <li>• IBS-C/CIC Agents</li> <li>• Sedative Hypnotics - Benzodiazepines</li> <li>• Sedative Hypnotics - Non-Benzodiazepines</li> <li>• Sedative Hypnotics - Non-Benzodiazepines, melatonin agonists</li> <li>• Skeletal Muscle Relaxants</li> <li>• Somatostatin Agents</li> <li>• Systemic Enzyme Inhibitors, CDK4/6 Inhibitors</li> <li>• Vesicular Monoamine Transporter 2 (VMAT) Inhibitors</li> </ul>